Navigation Links
InVitria Sponsors ESACT 2009 in Dublin, Ireland
Date:6/5/2009

InVitria, a leading supplier of performance enhancing cell culture media supplements, to sponsor the 21st Meeting of the European Society for Animal Cell Technology (ESACT) in Dublin, Ireland from June 7-10, 2009.

Fort Collins, CO June 5, 2009 / b3c newswire / – The world-renowned ESACT ‘09 gathering will serve as host to scientific experts from academia and industry brought together to find “Cellular Solutions for Clinical Challenges.” As one of the sponsors, InVitria will be sharing with attendees the powerful effects of its portfolio of cell culture media supplements developed to solve the regulatory and performance challenges facing the life science industry.

InVitria recently introduced a new product called ZAP-CHO, a performance enhancing cell culture media supplement designed to improve cell growth and antibody production in mammalian cell culture.

“ZAP-CHO improves CHO product development in chemically defined media that are completely free of animal components,” said Steve Pettit, Ph.D., Director of Cell Culture Development with InVitria.  “Previously, the performance enhancements gained with ZAP-CHO was only possible by utilizing animal components such as FBS (fetal bovine serum or fetal calf serum) in cell culture media,” said Dr. Pettit.

Additionally, ZAP-CHO speeds-up cell line development and seed train expansion and also offers cost saving benefits by reducing operating costs as well as capital investment.
 
Recent publications, along with customer results has validated that another of InVitria’s leading cell culture supplements, Cellastim, a recom
'/>"/>

b3c newswire

Page: 1 2

Related biology news :

1. InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
2. InVitria Announces Launch of Recombinant Albumin for Diagnostics
3. Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center
4. WPI professor receives Fulbright Scholarship to work on tissue engineering in Ireland
5. Darwin anniversary heralds new conservation research era for Northern Ireland
6. Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 target
7. For good or ill Ireland gains another mammal species
8. Ireland Cancer Center researchers advance stem cell gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... 1, 2011 A pathway whereby bacteria communicate with ... Hebrew University of Jerusalem. The discovery has important implications ... bacteria in the body. Bacteria are known to ... of extracellular signalling molecules, said Prof. Sigal Ben-Yehuda of ...
... is known to have cancer-protective properties, and shift work ... production. Shift work has been thought to have important ... increased risk of several cancers including breast, endometrial, prostate, ... study, researchers at Brigham and Women,s Hospital (BWH) found ...
... SEATTLE Twelve graduate students from institutes throughout ... Harold M. Weintraub Graduate Student Award sponsored by the ... Nominations were solicited internationally; the winners were selected on ... their work. , The recipients, all advanced students at ...
Cached Biology News:Shift work may be associated with decreased risk of skin cancer 22011 Harold M. Weintraub Graduate Student Award recipients announced 22011 Harold M. Weintraub Graduate Student Award recipients announced 3
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... 2014 The Latin American hardware encryption ... Latin America with analysis and forecast of revenue. This ... is expected to reach $2,366.8 million by 2018, at ... Browse through the TOC of the Latin American hardware ... in-depth analysis provided. It also provides a glimpse of ...
(Date:10/19/2014)... The Asian Automatic patient billing report ... and forecast of revenue. The Automatic patient billing market ... million by 2018, at a developing CAGR of 7.2% ... of the Asian Automatic patient billing market, to get ... provides a glimpse of the segmentation of this market ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... , ROCKVILLE, Md. , Aug. 6 ... today the appointment of Richard Douglas , Ph.D. to ... President, Corporate Development at Genzyme Corp.  As a leader of ... numerous acquisitions, licenses, joint ventures and strategic alliances as well ...
... Arizona State University researchers will get support from the ... next generations of lasers and infrared photodetectors. ... for an array of defense and commercial applications. ... Office grant through the defense department,s Multidisciplinary University Research ...
... Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced ... the Company,s lead product V-101, a topical cream under investigation for ... , , ... crossover clinical trial of 22 patients with rosacea was designed to ...
Cached Biology Technology:NOVAVAX Elects Richard H. Douglas to its Board of Directors 2NOVAVAX Elects Richard H. Douglas to its Board of Directors 3Looking to leap forward on laser and photodetector technologies 2Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea 2Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea 3
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Biology Products: